MaxCyte signs multi-platform technology license deal with Genentech to support cell therapy development
MXCT•MaxCyte enters technology license partnership with Genentech
MaxCyte entered a technology license partnership with Genentech to support development of multiple cell therapy programs.
The license gives Genentech access to MaxCyte’s ExPERT GTx platform across select research, clinical development, and manufacturing workflows.
The deal targets ex vivo cell-engineering applications, aiming to streamline progress from early discovery through cGMP manufacturing.
Related News
Cellectar BioSciences publishes corporate presentation on phospholipid drug conjugate radiotherapy pipeline, led by iopofosine I-131 in Waldenstrom macroglobulinemia
CLRB•
Wall St gains on chip stocks recovery; earnings draw focus
SPY•
